Ignite Creation Date:
2025-12-25 @ 2:00 AM
Ignite Modification Date:
2026-05-14 @ 8:28 AM
Study NCT ID:
NCT01777594
Status:
COMPLETED
Last Update Posted:
2016-08-23
First Post:
2013-01-18
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Study of G-202 (Mipsagargin) as Second-Line Therapy Following Sorafenib in Hepatocellular Carcinoma
Sponsor:
GenSpera, Inc.
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
G-202-003
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None